Pharmacokinetic and Pharmacodynamic Evaluation of the Novel CCR1 Antagonist CCX354 in Healthy Human Subjects: Implications for Selection of Clinical Dose

Autor: J. C. Jaen, AM Pennell, P Bekker, P. Zhang, Y. Wang, Y Zeng, Lisa Seitz, DJ Dairaghi, D.A. Johnson, S Miao, LS Ertl, T. J. Schall, J. P. Powers

Publikováno v: Clinical Pharmacology & Therapeutics. 89:726-734

The safety and pharmacokinetic (PK)/pharmacodynamic (PD) profile of the novel CCR1 antagonist CCX354 was evaluated in double-blind, placebo-controlled, single- and multiple-dose phase I studies (1–300 mg/day oral doses). CCX354 was well tolerated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b23d5e449093c08b90fee2b6b277264
https://doi.org/10.1038/clpt.2011.33

CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood.

Autor: Zhao BN; ChemoCentryx, Inc., Mountain View, CA 94043; and., Campbell JJ; ChemoCentryx, Inc., Mountain View, CA 94043; and jcampbell@ChemoCentryx.com., Salanga CL; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093., Ertl LS; ChemoCentryx, Inc., Mountain View, CA 94043; and., Wang Y; ChemoCentryx, Inc., Mountain View, CA 94043; and., Yau S; ChemoCentryx, Inc., Mountain View, CA 94043; and., Dang T; ChemoCentryx, Inc., Mountain View, CA 94043; and., Zeng Y; ChemoCentryx, Inc., Mountain View, CA 94043; and., McMahon JP; ChemoCentryx, Inc., Mountain View, CA 94043; and., Krasinski A; ChemoCentryx, Inc., Mountain View, CA 94043; and., Zhang P; ChemoCentryx, Inc., Mountain View, CA 94043; and., Kufareva I; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093., Handel TM; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093., Charo IF; ChemoCentryx, Inc., Mountain View, CA 94043; and., Singh R; ChemoCentryx, Inc., Mountain View, CA 94043; and., Schall TJ; ChemoCentryx, Inc., Mountain View, CA 94043; and.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2019 Dec 15; Vol. 203 (12), pp. 3157-3165. Date of Electronic Publication: 2019 Nov 01.

CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS).

Autor: Miao Z; ChemoCentryx, Inc., Mountain View, CA, United States of America., Ertl LS; ChemoCentryx, Inc., Mountain View, CA, United States of America., Newland D; ChemoCentryx, Inc., Mountain View, CA, United States of America., Zhao B; ChemoCentryx, Inc., Mountain View, CA, United States of America., Wang Y; ChemoCentryx, Inc., Mountain View, CA, United States of America., Zang X; ChemoCentryx, Inc., Mountain View, CA, United States of America., Campbell JJ; ChemoCentryx, Inc., Mountain View, CA, United States of America., Liu X; ChemoCentryx, Inc., Mountain View, CA, United States of America., Dang T; ChemoCentryx, Inc., Mountain View, CA, United States of America., Miao S; ChemoCentryx, Inc., Mountain View, CA, United States of America., Krasinski A; ChemoCentryx, Inc., Mountain View, CA, United States of America., Punna S; ChemoCentryx, Inc., Mountain View, CA, United States of America., Zeng Y; ChemoCentryx, Inc., Mountain View, CA, United States of America., McMahon J; ChemoCentryx, Inc., Mountain View, CA, United States of America., Zhang P; ChemoCentryx, Inc., Mountain View, CA, United States of America., Charo IF; ChemoCentryx, Inc., Mountain View, CA, United States of America., Schall TJ; ChemoCentryx, Inc., Mountain View, CA, United States of America., Singh R; ChemoCentryx, Inc., Mountain View, CA, United States of America.

Publikováno v: PloS one [PLoS One] 2018 Mar 21; Vol. 13 (3), pp. e0192405. Date of Electronic Publication: 2018 Mar 21 (Print Publication: 2018).

Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells.

Autor: Demir IE; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; ekin.demir@tum.de gueralp.ceyhan@tum.de., Kujundzic K; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Pfitzinger PL; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Saricaoglu ÖC; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Teller S; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Kehl T; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Reyes CM; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Ertl LS; ChemoCentryx, Inc., Mountain View, CA 94043., Miao Z; ChemoCentryx, Inc., Mountain View, CA 94043., Schall TJ; ChemoCentryx, Inc., Mountain View, CA 94043., Tieftrunk E; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Haller B; Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Diakopoulos KN; Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Kurkowski MU; Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Lesina M; Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Krüger A; Institute for Molecular Immunology and Experimental Oncology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Algül H; Department of Internal Medicine II, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Friess H; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany., Ceyhan GO; Department of Surgery, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; ekin.demir@tum.de gueralp.ceyhan@tum.de.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2017 Jan 03; Vol. 114 (1), pp. E85-E94. Date of Electronic Publication: 2016 Dec 16.

C5a receptor (CD88) blockade protects against MPO-ANCA GN.

Autor: Xiao H; Department of Pathology and Laboratory Medicine and., Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC

Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2014 Feb; Vol. 25 (2), pp. 225-31. Date of Electronic Publication: 2013 Oct 31.